Qiagen (QGEN) Upgraded by BidaskClub to “Hold”

Qiagen (NASDAQ:QGEN) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday.

Several other equities research analysts also recently weighed in on the stock. Morgan Stanley increased their target price on shares of Qiagen from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Wednesday. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday. Barclays reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a research note on Tuesday. Finally, Zacks Investment Research upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Qiagen currently has a consensus rating of “Hold” and a consensus price target of $39.13.

NASDAQ QGEN opened at $36.35 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07. Qiagen has a 1 year low of $30.20 and a 1 year high of $39.45.

Qiagen (NASDAQ:QGEN) last announced its earnings results on Monday, October 29th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.02. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The business had revenue of $377.90 million during the quarter, compared to the consensus estimate of $380.11 million. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Sell-side analysts predict that Qiagen will post 1.34 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Strs Ohio raised its holdings in Qiagen by 14.1% during the third quarter. Strs Ohio now owns 12,462 shares of the company’s stock worth $472,000 after purchasing an additional 1,543 shares in the last quarter. Toronto Dominion Bank raised its holdings in Qiagen by 17.3% during the second quarter. Toronto Dominion Bank now owns 17,214 shares of the company’s stock worth $627,000 after purchasing an additional 2,539 shares in the last quarter. Parallel Advisors LLC raised its holdings in Qiagen by 548.5% during the third quarter. Parallel Advisors LLC now owns 3,210 shares of the company’s stock worth $122,000 after purchasing an additional 2,715 shares in the last quarter. First Bank & Trust raised its holdings in Qiagen by 156.0% during the second quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after purchasing an additional 3,003 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in Qiagen by 16.8% during the second quarter. BNP Paribas Arbitrage SA now owns 26,052 shares of the company’s stock worth $942,000 after purchasing an additional 3,738 shares in the last quarter. 62.23% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Read More: Yield Curve

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply